CN115317492A - 化合物用于制备预防、治疗或改善疼痛的药物的用途 - Google Patents
化合物用于制备预防、治疗或改善疼痛的药物的用途 Download PDFInfo
- Publication number
- CN115317492A CN115317492A CN202210621699.8A CN202210621699A CN115317492A CN 115317492 A CN115317492 A CN 115317492A CN 202210621699 A CN202210621699 A CN 202210621699A CN 115317492 A CN115317492 A CN 115317492A
- Authority
- CN
- China
- Prior art keywords
- formula
- hydrogen
- iia
- aryl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 93
- 239000003814 drug Substances 0.000 title claims abstract description 58
- 208000002193 Pain Diseases 0.000 title claims abstract description 44
- 238000004519 manufacturing process Methods 0.000 claims abstract description 11
- 230000002265 prevention Effects 0.000 claims abstract description 11
- -1 C 2 -C 6 Alkenyl radical Chemical class 0.000 claims description 55
- 125000000623 heterocyclic group Chemical group 0.000 claims description 48
- 125000003118 aryl group Chemical group 0.000 claims description 43
- 229910052739 hydrogen Inorganic materials 0.000 claims description 43
- 239000001257 hydrogen Substances 0.000 claims description 43
- 125000001072 heteroaryl group Chemical group 0.000 claims description 41
- 206010028980 Neoplasm Diseases 0.000 claims description 37
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 34
- 229940079593 drug Drugs 0.000 claims description 30
- 102000004602 Aldo-Keto Reductase Family 1 Member C3 Human genes 0.000 claims description 25
- 108010065942 Prostaglandin-F synthase Proteins 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 23
- 201000011510 cancer Diseases 0.000 claims description 20
- 150000003335 secondary amines Chemical class 0.000 claims description 20
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 19
- 239000002246 antineoplastic agent Substances 0.000 claims description 18
- 229940041181 antineoplastic drug Drugs 0.000 claims description 18
- 150000002431 hydrogen Chemical group 0.000 claims description 18
- 239000012453 solvate Substances 0.000 claims description 18
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 229910052717 sulfur Inorganic materials 0.000 claims description 15
- 229940127089 cytotoxic agent Drugs 0.000 claims description 14
- 239000002254 cytotoxic agent Substances 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 11
- 206010061218 Inflammation Diseases 0.000 claims description 11
- 230000004054 inflammatory process Effects 0.000 claims description 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 125000003342 alkenyl group Chemical group 0.000 claims description 7
- 229940100198 alkylating agent Drugs 0.000 claims description 7
- 239000002168 alkylating agent Substances 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 6
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 5
- 125000001931 aliphatic group Chemical group 0.000 claims description 4
- 150000001450 anions Chemical class 0.000 claims description 4
- 238000005906 dihydroxylation reaction Methods 0.000 claims description 4
- 125000001033 ether group Chemical group 0.000 claims description 4
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 claims description 4
- 125000003107 substituted aryl group Chemical group 0.000 claims description 4
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims description 4
- 230000008030 elimination Effects 0.000 claims description 3
- 238000003379 elimination reaction Methods 0.000 claims description 3
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 150000001447 alkali salts Chemical class 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000004437 phosphorous atom Chemical group 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 239000002253 acid Chemical class 0.000 claims 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 26
- 125000004432 carbon atom Chemical group C* 0.000 description 22
- 125000005842 heteroatom Chemical group 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 14
- 239000000186 progesterone Substances 0.000 description 13
- 229960003387 progesterone Drugs 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 12
- NWGZZGNICQFUHV-OAHLLOKOSA-N C[C@@H](OP(=O)(N1CC1)N1CC1)C1=CC(OC2=CC(=CC=C2)C(=O)N(C)C)=C(C=C1)[N+]([O-])=O Chemical compound C[C@@H](OP(=O)(N1CC1)N1CC1)C1=CC(OC2=CC(=CC=C2)C(=O)N(C)C)=C(C=C1)[N+]([O-])=O NWGZZGNICQFUHV-OAHLLOKOSA-N 0.000 description 11
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 10
- 229960001342 dinoprost Drugs 0.000 description 10
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 10
- 229960002986 dinoprostone Drugs 0.000 description 10
- 229940002612 prodrug Drugs 0.000 description 10
- 239000000651 prodrug Substances 0.000 description 10
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 8
- 125000002947 alkylene group Chemical group 0.000 description 8
- 125000005843 halogen group Chemical group 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 241000282567 Macaca fascicularis Species 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 229960003712 propranolol Drugs 0.000 description 6
- 150000003180 prostaglandins Chemical class 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 125000006574 non-aromatic ring group Chemical group 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- RWBRUCCWZPSBFC-RXRZZTMXSA-N (20S)-20-hydroxypregn-4-en-3-one Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](O)C)[C@@]1(C)CC2 RWBRUCCWZPSBFC-RXRZZTMXSA-N 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 238000010606 normalization Methods 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 206010042863 synovial sarcoma Diseases 0.000 description 4
- 125000001544 thienyl group Chemical group 0.000 description 4
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 3
- 108010092160 Dactinomycin Proteins 0.000 description 3
- 208000006168 Ewing Sarcoma Diseases 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
- 229960000975 daunorubicin Drugs 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 description 3
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 201000010260 leiomyoma Diseases 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- PXGPLTODNUVGFL-YNNPMVKQSA-N prostaglandin F2alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-YNNPMVKQSA-N 0.000 description 3
- 125000004151 quinonyl group Chemical group 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229960001052 streptozocin Drugs 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000011593 sulfur Chemical group 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- XRBSKUSTLXISAB-XVVDYKMHSA-N (5r,6r,7r,8r)-8-hydroxy-7-(hydroxymethyl)-5-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxole-6-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H](CO)[C@@H]2C(O)=O)=C1 XRBSKUSTLXISAB-XVVDYKMHSA-N 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- BTOTXLJHDSNXMW-POYBYMJQSA-N 2,3-dideoxyuridine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(=O)NC(=O)C=C1 BTOTXLJHDSNXMW-POYBYMJQSA-N 0.000 description 2
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 2
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 2
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 206010051810 Angiomyolipoma Diseases 0.000 description 2
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 2
- MKQWTWSXVILIKJ-LXGUWJNJSA-N Chlorozotocin Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC(=O)N(N=O)CCCl MKQWTWSXVILIKJ-LXGUWJNJSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 208000009738 Connective Tissue Neoplasms Diseases 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 239000012624 DNA alkylating agent Substances 0.000 description 2
- 229940126161 DNA alkylating agent Drugs 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- HPHUVLMMVZITSG-UHFFFAOYSA-N Etiracetam Chemical compound CCC(C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-UHFFFAOYSA-N 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 description 2
- 229920001491 Lentinan Polymers 0.000 description 2
- 206010025219 Lymphangioma Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 229930187135 Olivomycin Natural products 0.000 description 2
- 239000008896 Opium Substances 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 2
- 208000008601 Polycythemia Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 2
- 208000034541 Rare lymphatic malformation Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 2
- 229960004176 aclarubicin Drugs 0.000 description 2
- 229930183665 actinomycin Natural products 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 229960000473 altretamine Drugs 0.000 description 2
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 2
- 229960001220 amsacrine Drugs 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 208000009887 angiolipoma Diseases 0.000 description 2
- 208000028435 angiomyxoma Diseases 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 229960002756 azacitidine Drugs 0.000 description 2
- 125000004931 azocinyl group Chemical group N1=C(C=CC=CC=C1)* 0.000 description 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 2
- 229950008548 bisantrene Drugs 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 108700002839 cactinomycin Proteins 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 2
- XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 description 2
- 229960003261 carmofur Drugs 0.000 description 2
- 229950001725 carubicin Drugs 0.000 description 2
- 108010047060 carzinophilin Proteins 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 229960001480 chlorozotocin Drugs 0.000 description 2
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 229960003901 dacarbazine Drugs 0.000 description 2
- 229950011487 enocitabine Drugs 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 229960001842 estramustine Drugs 0.000 description 2
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229950007353 etiracetam Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 229960000961 floxuridine Drugs 0.000 description 2
- 229960000390 fludarabine Drugs 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 229960002074 flutamide Drugs 0.000 description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
- 229960004783 fotemustine Drugs 0.000 description 2
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 229960001330 hydroxycarbamide Drugs 0.000 description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
- 229960002411 imatinib Drugs 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000005956 isoquinolyl group Chemical group 0.000 description 2
- 229940115286 lentinan Drugs 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 208000012804 lymphangiosarcoma Diseases 0.000 description 2
- 208000017830 lymphoblastoma Diseases 0.000 description 2
- 208000025036 lymphosarcoma Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960004961 mechlorethamine Drugs 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- 229960000901 mepacrine Drugs 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 2
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
- 229960005485 mitobronitol Drugs 0.000 description 2
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
- 229960000951 mycophenolic acid Drugs 0.000 description 2
- 208000009091 myxoma Diseases 0.000 description 2
- NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 2
- 208000014761 nasopharyngeal type undifferentiated carcinoma Diseases 0.000 description 2
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229960001420 nimustine Drugs 0.000 description 2
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 2
- CZDBNBLGZNWKMC-MWQNXGTOSA-N olivomycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1)O[C@H]1O[C@@H](C)[C@H](O)[C@@H](OC2O[C@@H](C)[C@H](O)[C@@H](O)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@H](O)[C@H](OC)[C@H](C)O1 CZDBNBLGZNWKMC-MWQNXGTOSA-N 0.000 description 2
- 229950005848 olivomycin Drugs 0.000 description 2
- 229960001027 opium Drugs 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 229960000952 pipobroman Drugs 0.000 description 2
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 2
- 229960001221 pirarubicin Drugs 0.000 description 2
- 229960003171 plicamycin Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229960004694 prednimustine Drugs 0.000 description 2
- 150000003141 primary amines Chemical group 0.000 description 2
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 2
- 229960000624 procarbazine Drugs 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 229960002185 ranimustine Drugs 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- PVYJZLYGTZKPJE-UHFFFAOYSA-N streptonigrin Chemical compound C=1C=C2C(=O)C(OC)=C(N)C(=O)C2=NC=1C(C=1N)=NC(C(O)=O)=C(C)C=1C1=CC=C(OC)C(OC)=C1O PVYJZLYGTZKPJE-UHFFFAOYSA-N 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 229960001674 tegafur Drugs 0.000 description 2
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 2
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 description 2
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 2
- 229960001099 trimetrexate Drugs 0.000 description 2
- HDZZVAMISRMYHH-LITAXDCLSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O HDZZVAMISRMYHH-LITAXDCLSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 229950009811 ubenimex Drugs 0.000 description 2
- 229960001055 uracil mustard Drugs 0.000 description 2
- SPDZFJLQFWSJGA-UHFFFAOYSA-N uredepa Chemical compound C1CN1P(=O)(NC(=O)OCC)N1CC1 SPDZFJLQFWSJGA-UHFFFAOYSA-N 0.000 description 2
- 229950006929 uredepa Drugs 0.000 description 2
- RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229950009268 zinostatin Drugs 0.000 description 2
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- XRBSKUSTLXISAB-UHFFFAOYSA-N (7R,7'R,8R,8'R)-form-Podophyllic acid Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C(CO)C2C(O)=O)=C1 XRBSKUSTLXISAB-UHFFFAOYSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- VNBAOSVONFJBKP-UHFFFAOYSA-N 2-chloro-n,n-bis(2-chloroethyl)propan-1-amine;hydrochloride Chemical compound Cl.CC(Cl)CN(CCCl)CCCl VNBAOSVONFJBKP-UHFFFAOYSA-N 0.000 description 1
- HZQKCJMOQHMNTI-UHFFFAOYSA-N 4-amino-2-methyl-3-oxobutanoic acid Chemical compound OC(=O)C(C)C(=O)CN HZQKCJMOQHMNTI-UHFFFAOYSA-N 0.000 description 1
- WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 description 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical class C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 208000007569 Giant Cell Tumors Diseases 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- HRHKSTOGXBBQCB-UHFFFAOYSA-N Mitomycin E Natural products O=C1C(N)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)C3N(C)C3CN12 HRHKSTOGXBBQCB-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- SBGPASZOVGSOFJ-FEBARNBZSA-N Nitrarine Natural products N1C2=CC=CC=C2C(CCN23)=C1[C@H]3[C@@H]1CC[C@@H]2[C@@H]2[C@H]1NCCC2 SBGPASZOVGSOFJ-FEBARNBZSA-N 0.000 description 1
- SYNHCENRCUAUNM-UHFFFAOYSA-N Nitrogen mustard N-oxide hydrochloride Chemical compound Cl.ClCC[N+]([O-])(C)CCCl SYNHCENRCUAUNM-UHFFFAOYSA-N 0.000 description 1
- KGTDRFCXGRULNK-UHFFFAOYSA-N Nogalamycin Natural products COC1C(OC)(C)C(OC)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=C4C5(C)OC(C(C(C5O)N(C)C)O)OC4=C3C3=O)=C3C=C2C(C(=O)OC)C(C)(O)C1 KGTDRFCXGRULNK-UHFFFAOYSA-N 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 235000008753 Papaver somniferum Nutrition 0.000 description 1
- 240000001090 Papaver somniferum Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100038239 Protein Churchill Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- UMILHIMHKXVDGH-UHFFFAOYSA-N Triethylene glycol diglycidyl ether Chemical compound C1OC1COCCOCCOCCOCC1CO1 UMILHIMHKXVDGH-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 229930188522 aclacinomycin Natural products 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000019493 atypical carcinoid tumor Diseases 0.000 description 1
- 229950011321 azaserine Drugs 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229950009908 cactinomycin Drugs 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000004623 carbolinyl group Chemical group 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- ZYVSOIYQKUDENJ-WKSBCEQHSA-N chromomycin A3 Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1OC(C)=O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@@H](C)[C@H](OC(C)=O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1C[C@@H](O)[C@@H](OC)[C@@H](C)O1 ZYVSOIYQKUDENJ-WKSBCEQHSA-N 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- ONCCWDRMOZMNSM-FBCQKBJTSA-N compound Z Chemical compound N1=C2C(=O)NC(N)=NC2=NC=C1C(=O)[C@H]1OP(O)(=O)OC[C@H]1O ONCCWDRMOZMNSM-FBCQKBJTSA-N 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960005052 demecolcine Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- RXPRRQLKFXBCSJ-UHFFFAOYSA-N dl-Vincamin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-UHFFFAOYSA-N 0.000 description 1
- 108010067396 dornase alfa Proteins 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229960005237 etoglucid Drugs 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 1
- 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- MQXVYODZCMMZEM-ZYUZMQFOSA-N mannomustine Chemical compound ClCCNC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CNCCCl MQXVYODZCMMZEM-ZYUZMQFOSA-N 0.000 description 1
- 229950008612 mannomustine Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 1
- HRHKSTOGXBBQCB-VFWICMBZSA-N methylmitomycin Chemical compound O=C1C(N)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@@]1(OC)[C@H]3N(C)[C@H]3CN12 HRHKSTOGXBBQCB-VFWICMBZSA-N 0.000 description 1
- QTFKTBRIGWJQQL-UHFFFAOYSA-N meturedepa Chemical compound C1C(C)(C)N1P(=O)(NC(=O)OCC)N1CC1(C)C QTFKTBRIGWJQQL-UHFFFAOYSA-N 0.000 description 1
- 229950009847 meturedepa Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960003539 mitoguazone Drugs 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229950007856 mofetil Drugs 0.000 description 1
- FOYWNSCCNCUEPU-UHFFFAOYSA-N mopidamol Chemical compound C12=NC(N(CCO)CCO)=NC=C2N=C(N(CCO)CCO)N=C1N1CCCCC1 FOYWNSCCNCUEPU-UHFFFAOYSA-N 0.000 description 1
- 229950010718 mopidamol Drugs 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- VIJMMQUAJQEELS-UHFFFAOYSA-N n,n-bis(ethenyl)ethenamine Chemical compound C=CN(C=C)C=C VIJMMQUAJQEELS-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- SBGPASZOVGSOFJ-CHBAHTGHSA-N nitrarine Chemical compound N1C2=CC=CC=C2C(CCN23)=C1[C@H]3[C@H]1CC[C@@H]2[C@H]2[C@@H]1NCCC2 SBGPASZOVGSOFJ-CHBAHTGHSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 210000000929 nociceptor Anatomy 0.000 description 1
- 108091008700 nociceptors Proteins 0.000 description 1
- KGTDRFCXGRULNK-JYOBTZKQSA-N nogalamycin Chemical compound CO[C@@H]1[C@@](OC)(C)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=C4[C@@]5(C)O[C@H]([C@H]([C@@H]([C@H]5O)N(C)C)O)OC4=C3C3=O)=C3C=C2[C@@H](C(=O)OC)[C@@](C)(O)C1 KGTDRFCXGRULNK-JYOBTZKQSA-N 0.000 description 1
- 229950009266 nogalamycin Drugs 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000005968 oxazolinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 201000002530 pancreatic endocrine carcinoma Diseases 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- GJSGGHOYGKMUPT-UHFFFAOYSA-N phenoxathiine Chemical compound C1=CC=C2OC3=CC=CC=C3SC2=C1 GJSGGHOYGKMUPT-UHFFFAOYSA-N 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 229950004406 porfiromycin Drugs 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000030266 primary brain neoplasm Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 1
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- WOLQREOUPKZMEX-UHFFFAOYSA-N pteroyltriglutamic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(=O)NC(CCC(=O)NC(CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C=C1 WOLQREOUPKZMEX-UHFFFAOYSA-N 0.000 description 1
- 229940107568 pulmozyme Drugs 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000004477 skin sarcoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000004525 thiadiazinyl group Chemical group S1NN=C(C=C1)* 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229960002726 vincamine Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/564—Three-membered rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
本申请是2019年4月26日提交的申请号为201980001988.4、发明名称为“化合物用于制备预防、治疗或改善疼痛的药物的用途”的中国发明专利申请的分案申请。
技术领域
本发明涉及专利申请PCT/US2016/021581、专利申请 PCT/US2016/025665和专利申请PCT/US2016/062114中公开的化合物在制备预防、治疗或改善疼痛的药物中的用途。
背景技术
疼痛是一种因实际的或潜在的组织损伤而产生的痛苦感觉,既是机体的一种保护性反应,也是临床许多疾病的常见症状。
疼痛的治疗在医学上是非常重要的。传统镇痛药物主要包括阿片类药物和非甾体抗炎药。阿片类药物是从阿片(罂粟)中提取的生物碱及体内外的衍生物,其与中枢特异性受体相互作用,能缓解疼痛,镇痛作用强;但是长期使用易导致耐受性、依赖性和成瘾性,并有呼吸抑制、中枢镇静等不良反应,目前用于急性锐痛和癌性剧痛等。非甾体抗炎药是一类不含有甾体结构的抗炎药,具有抗炎、抗风湿、止痛、退热和抗凝血等作用,在临床上广泛用于骨关节炎、类风湿性关节炎、多种发热和各种疼痛症状的缓解;但是仅发挥中等程度镇痛作用,适用于轻度和中度的慢性钝痛,但对直接刺激感觉末梢引起的锐痛无效,此外还具有消化道出血和心脏毒性等不良反应。
因此本领域仍需要开发新型的镇痛药物。
发明内容
为了解决上述技术问题,本发明基于专利申请PCT/US2016/021581 (WO2016/145092)、专利申请PCT/US2016/025665(WO2016/161342) 和专利申请PCT/US2016/062114(WO2017/087428)中公开的化合物或者这些化合物的药学上可接受的盐或溶剂合物,提供所述化合物或者其药学上可接受的盐或溶剂合物在制备预防、治疗或改善疼痛的药物中的用途。
已经证明,专利申请PCT/US2016/021581、PCT/US2016/025665和 PCT/US2016/062114中公开的化合物作为国际首创的、高度肿瘤选择性的小分子靶向治疗药物,在多种临床前细胞和动物模型中已表现出非常出色的抗癌效果。这些化合物作为醛酮还原酶AKR1C3特异性底物,可仅在AKR1C3高表达的癌细胞内快速有效地还原,从而释放细胞毒素导致高选择性的癌细胞杀伤药效。
研发团队构想,由于上述发明申请公开的化合物作为醛酮还原酶 AKR1C3特异性底物(以下简称特异性底物),其实际是一种抗癌烷化剂前药,其特异性地在醛酮还原酶AKR1C3的作用下被活化并代谢得到具有细胞毒性的烷化剂,以AST-2870(上述PCT/US2016/021581中公开的化合物TH-2870)为例:
其中AST-3424为前述三个PCT申请中的2870化合物的S构型异构体。
也就是说,醛酮还原酶AKR1C3需要和特异性底物结合。
根据研究文献(Samad T A,Moore K A,Sapirstein A,et al. Interleukin-1[beta]-mediated induction of Cox-2in the CNS contributes to inflammatory painhypersensitivity[J].Nature,2001,410(6827):471-5.; Baojian Z,Yanbing Y,Gele A,et al.Tanshinone IIA Attenuates Diabetic Peripheral Neuropathic Pain inExperimental Rats via Inhibiting Inflammation[J].Evidence-Based Complementaryand Alternative Medicine,2018,2018:1-8.;Lovering A,Ride J,Bunce C,etal.Crystal Structures of Prostaglandin D2 11-Ketoreductase(AKR1C3)in Complexwith the Nonsteroidal Anti-Inflammatory Drugs Flufenamic Acid andIndomethacin[J].Cancer Research,2004,64(5):1802-1810.;Matsuura K, ShiraishiH,Hara A,et al.Identification of a principal mRNA species for human 3alpha-hydroxysteroid dehydrogenase isoform(AKR1C3)that exhibits high prostaglandinD2 11-ketoreductase activity.[J].Journal of Biochemistry,1998,124(5):940-6.)可知醛酮还原酶AKR1C3在前列腺素 H2/D2转化为前列腺素E2/F2的生化路径中扮演重要的催化作用,在无AST-3424前药的条件下,前列腺素转化过程如图2所示。
发明人设想,由于特异性底物能够和醛酮还原酶AKR1C3结合,能不能成为醛酮还原酶AKR1C3的抑制剂,从而发挥降低前列腺素 E2/F2水平,起到预防、治疗或改善癌症或炎症引起的疼痛的作用呢?在有AST-3424前药的条件下,可能的前列腺素转化过程如图3所示。
对于以上设想,发明人设计了实验进行验证,实验证实上述的特异性底物即以过表达醛酮还原酶AKR1C3为标靶的DNA烷化剂能抑制醛酮还原酶AKR1C3的活性,而且动物实验证实,其能降低血液中的前列腺素E2/F2的含量,据此,可以证明上述的特异性底物具有止疼作用。
关于上述化合物的止疼作用,特别是它们在制备预防、治疗或改善癌症或炎症引起的疼痛的药物中的用途,本发明提供的技术方案如下。
一方面,本发明提供式I化合物或者其药学上可接受的盐或溶剂合物在制备用于预防、治疗或改善疼痛的药物中的用途,
其中,
X10是O、S、SO或SO2;
A是C6-C10芳基或取代芳基、5-15元杂芳基或取代杂芳基或 -N=CR1R2;其中,R1和R2各自独立地是氢、C1-C6烷基、C3-C8环烷基、 C6-C10芳基、4-15元杂环、5-15元杂芳基、醚、-CONR13R14或-NR13COR14;
X、Y和Z各自独立地是氢、CN、卤基、C1-C6烷基、C2-C6烯基、 C2-C6炔基、C3-C8环烷基、C6-C10芳基、4-15元杂环、5-15元杂芳基、醚、-CONR13R14或-NR13COR14;
R是氢、C1-C6烷基、C2-C6烯基、C2-C6炔基、C3-C8环烷基、C6-C10芳基、4-15元杂环、5-15元杂芳基、醚、-CONR13R14或-NR13COR14;
R13和R14各自独立地是氢、C1-C6烷基、C3-C8环烷基、C6-C10芳基、4-15元杂环、5-15元杂芳基或醚,或者R13和R14与其所键结的氮原子一起形成5-7元杂环基;
T包含胺基磷酸酯烷化剂;且
其中所述烷基、烯基、炔基、环烷基、芳基、杂环、杂芳基、醚基视情况经取代。
优选地,其中,所述化合物具有式I-A
其余变量如上文所定义。
或者,X10是S。
更优选地,在所述化合物中,T是OP(Z1)(NR30CH2CH2X1)2、 OP(Z1)(NR30 2)(N(CH2CH2X1)2)、OP(Z1)(N(CH2)2)2或 OP(Z1)(N(CH2CH2X1)2)2,其中R30各自独立地是氢或C1-C6烷基,或2个 R30基团与其所键结的氮原子一起形成5-7元杂环基,Z1是O或S,且X1是Cl、Br或OMs或其他离去基团。
进一步优选地,在所述化合物中,T是OP(Z1)(NHCH2CH2Cl)2、 OP(Z1)(NHCH2CH2Br)2、OP(Z1)(NH2)(N(CH2CH2X1)2)、 OP(Z1)(N(CH2)2)2或OP(Z1)(N(CH2CH2Cl)2)2,其中Z1是O或S,且X1是 Cl、Br或OMs。
根据本发明的具体实施方式,在所述化合物中,Z1是O或S。
根据本发明的具体实施方式,在所述化合物中,T是 OP(O)(N(CH2CH2))2、OP(O)(NHCH2CH2Cl)2、OP(O)(NHCH2CH2Br)2或OP(O)(NH2)(N(CH2CH2Cl)2)。
根据本发明的具体实施方式,在所述化合物中,Z是氢。
根据本发明的具体实施方式,在所述化合物中,X是氢。
根据本发明的具体实施方式,在所述化合物中,Y是氢或卤基。
优选地,在所述化合物中,A是视情况经取代的C6-C10芳基。
更优选地,在所述化合物中,A是视情况经取代的苯基。
优选地,在所述化合物中,A是视情况经取代的5-15元杂芳基。
更优选地,在所述化合物中,A是视情况经取代的吡啶基。
更优选地,在所述化合物中,A是-N=CR1R2,其中R1和R2如上文所定义。
根据本发明的具体实施方式,在所述化合物中,R是氢。
优选地,在所述化合物中,R是C1-C6烷基。
根据本发明的具体实施方式,在所述化合物中,R是甲基。关于本文所述用途,所述化合物包括个别非镜像异构物及其他几何异构物及镜像异构物、及镜像异构物、非镜像异构物及除非镜像异构物以外的几何异构物的混合物。
本发明上文所示式I化合物见PCT申请PCT/US2016/021581,其国际公开文本为WO2016/145092,对应的中国专利申请为 CN201680015078.8,其公开文本为CN107530556A,该专利申请的全部内容以引用方式并入本文。在该PCT申请中,就化合物的通式结构、基团取代情况、优选通式结构、优选具体化合物等等均进行了详细说明,所涉及到的全部内容均在此引用。因此,本发明就上文所示化合物或者其药学上可接受的盐或溶剂合物在制备用于预防、治疗或改善疼痛的药物中的用途涵盖了PCT申请PCT/US2016/021581中提供的关于化合物或者其药学上可接受的盐或溶剂合物的全部内容。
另一方面,本发明提供式II化合物或者其药学上可接受的盐或溶剂合物在制备用于预防、治疗或改善疼痛的药物中的用途,
其中
X10是O、S、SO或SO2;
A是C6-C10芳基或取代芳基、5-15元杂芳基或取代杂芳基或 -N=CR1R2;其中,R1和R2各自独立地是氢、C1-C6烷基、C3-C8环烷基、 C6-C10芳基、4-15元杂环、5-15元杂芳基、醚、-CONR13R14或-NR13COR14;
X、Y和Z各自独立地是氢、CN、卤基、C1-C6烷基、C2-C6烯基、 C2-C6炔基、C3-C8环烷基、C6-C10芳基、4-15元杂环、5-15元杂芳基、醚、-CONR13R14或-NR13COR14;
每个R独立地是氢、C1-C6烷基、C2-C6烯基、C2-C6炔基、C3-C8环烷基、C6-C10芳基、4-15元杂环、5-15元杂芳基、醚、-CONR13R14或 -NR13COR14;
R13和R14各自独立地是氢、C1-C6烷基、C3-C8环烷基、C6-C10芳基、 4-15元杂环、5-15元杂芳基或醚,或者R13和R14与其所键结的氮原子一起形成5-7元杂环基;
L1和D定义如下:
L1选自:
其中,R40和R41独立地是氢、C1-C6烷基、C2-C6烯基、C2-C6炔基、 C3-C8环烷基、C6-C10芳基、4-15元杂环或5-15元杂芳基;R42是视情况经1-3个C1-C6烷基取代的C2-C3伸烷基或伸杂烷基;V(-)为任何阴离子,较佳为医药学上可接受的阴离子;和
D是使得D-OH为抗癌药物的部分,其中OH为脂族羟基或酚羟基,或为如本文提供的附接至磷原子的OH部分;换言之,D是抗癌药物 D-OH脱去羟基后剩余的基团;
或者
L1为:
其中R40如上文所定义,R43为氢或与D一起形成杂环,且苯基部分视情况经取代;和
D是使得D-NR43H为抗癌药物的部分;换言之,D是抗癌药物 D-NR43H脱去氨基或胺后剩余的基团;
或者
其中R40、R41和V如上文所定义;和
D是含有伯胺或仲胺的抗癌药物,其中该伯胺或该仲胺键接至L1;且
其中所述烷基、烯基、炔基、环烷基、芳基、杂环、杂芳基、醚基视情况经取代。
优选地,其中,所述化合物具有式II-A
其余变量如上文所定义。
在另一实施例中,X10为S。
更优选地,其中,所述化合物具有式IIA-1:
其余变量如上文所定义,且D是含有一级胺基或二级胺基的细胞毒性剂HNR43-D的一部分;换言之,D是细胞毒性剂HNR43-D脱去一级胺基或二级胺基后剩余的基团。
或者,更优选地,其中,所述化合物具有式IIA-2或IIA-3:
其余变量如上文所定义,且D是含有至少一个羟基的细胞毒性剂 HO-D的一部分;换言之,D是细胞毒性剂HO-D脱去羟基后剩余的基团。
或者,更优选地,其中,所述化合物具有式IIA-4、IIA-6或IIA-6-i:
其中变量如上文所定义;其中,IIA-4中,HO-D为含有至少一个羟基的细胞毒性剂;换言之,D是含有至少一个羟基的细胞毒性剂HO-D 的一部分,或者说D是细胞毒性剂HO-D脱去羟基后剩余的基团;在 IIA-6-i中,DNR40R41是药物;换言之,D是使得DNR40R41为抗癌药物的部分,或者D是抗癌药物DNR40R41脱离NR40R41的部分;且在IIA-6中, D是含有仲胺的药物,其中该仲胺键接至亚甲基,换言之,D是含有仲胺的药物,且通过其含有的仲胺键接至亚甲基、进而与-NR40R41相连,如以上所示。
或者,更优选地,其中,所述化合物具有式IIA-5或IIA-7:
其中变量如上文所定义;其中,在IIA-5中,DNR40R41是药物;换言之,D是使得DNR40R41为抗癌药物的部分,或者D是抗癌药物 DNR40R41脱离NR40R41的部分;在IIA-7中,D是含有仲胺的药物,其中该仲胺键接至亚甲基,如以上所示。
根据本发明的具体实施方式,在所述化合物中,Z是氢。
根据本发明的具体实施方式,在所述化合物中,X是氢。
根据本发明的具体实施方式,在所述化合物中,Y是氢或卤基。
优选地,在所述化合物中,A是视情况经取代的C6-C10芳基。
更优选地,在所述化合物中,A是视情况经取代的苯基。
优选地,在所述化合物中,A是视情况经取代的5-15元杂芳基。
更优选地,在所述化合物中,A是视情况经取代的吡啶基。
更优选地,在所述化合物中,A是-N=CR1R2,其中R1和R2如上文所定义。
根据本发明的具体实施方式,在所述化合物中,每个R是氢。
优选地,在所述化合物中,R基团中的一个是氢且另一个是C1-C6烷基,或其中R基团均是如上文所定义的非氢取代基。
根据本发明的具体实施方式,在所述化合物中,R是甲基。
优选地,在所述化合物中,R40、R41和R43各自独立地是氢或甲基且 R42是-CH2-CH2-或CH2-C(Me)2-。
特别地,如本文中所用,D不包括胺基磷酸酯烷基化剂,诸如 -P(Z1)(NR30CH2CH2X1)2、-P(Z1)(NR30 2)(N(CH2CH2X1)2)、 -P(Z1)(N(CH2CH2))2或-P(Z1)(N(CH2CH2X1)2)2,其中每个R30独立地是氢或C1-C6烷基,或2个R30与其所结合的氮原子一起形成5-7元杂环基,Z1是O或S,且X1是Cl、Br或OMs,或另一离去基团。
关于本文所述用途,所述化合物包括个别非镜像异构物及其他几何异构物及镜像异构物、及镜像异构物、非镜像异构物及除非镜像异构物以外的几何异构物的混合物。
本发明上文所示式II化合物见PCT申请PCT/US2016/025665,其国际公开文本为WO2016/161342,对应的中国申请为CN201680020013.2,其公开文本为CN108136214A,该专利申请的全部内容以引用方式并入本文。在该PCT申请中,就化合物的通式结构、基团取代情况、优选通式结构、优选具体化合物等等均进行了详细说明,所涉及到的全部内容均在此引用。因此,本发明就上文所示化合物或者其药学上可接受的盐或溶剂合物在制备用于预防、治疗或改善疼痛的药物中的用途涵盖了PCT申请PCT/US2016/025665中提供的关于化合物或者其药学上可接受的盐或溶剂合物的全部内容。
根据本发明的具体实施方式,所述化合物I为如下所示的化合物 AST-3424:
关于本文所述用途,所述化合物还可以盐的形式使用,即本发明提供所示化合物的药学上可接受的盐在制备用于预防、治疗或改善疼痛的药物中的用途。其中,所述盐可以为碱式盐,包括所述化合物与无机碱 (例如碱金属氢氧化物、碱土金属氢氧化物等)或与有机碱(例如单乙醇胺、二乙醇胺或三乙醇胺等)形成的盐。或者,所述盐可以为酸式盐,包括所述化合物与无机酸(例如盐酸、氢溴酸、氢碘酸、硝酸、高氯酸、硫酸或磷酸等)或与有机酸(例如甲磺酸、三氟甲磺酸、乙磺酸、苯磺酸、对甲苯磺酸、富马酸、草酸、马来酸、柠檬酸等)形成的盐。选择和制备化合物的可接受的盐和溶剂化物等是本领域公知技术。
关于本文所述用途,所述化合物还可以溶剂合物的形式使用,即本发明提供所示化合物的药学上可接受的溶剂合物在制备用于预防、治疗或改善疼痛的药物中的用途。其中,所述溶剂合物为水合物、醇合物等。
关于本文所述用途,所述疼痛为癌症引起的疼痛,癌症包括但不限于:肺癌、非小细胞肺癌、肝癌、胰腺癌、胃癌、骨癌、食道癌、乳房癌、前列腺癌、睾丸癌、结肠癌、卵巢癌、膀胧癌、子宫颈癌、黑色素瘤、鳞状细胞癌、基底细胞癌、腺癌、汗腺癌、皮脂腺癌、乳头状癌、乳头状腺癌、囊性腺癌、囊性癌、髓状癌、支气管癌、骨细胞癌、上皮癌、胆管癌、绒毛膜癌、胚癌、精原细胞癌、维尔姆斯癌、胶质细胞癌、星形细胞瘤、成神经管细胞瘤、颅咽管瘤、室管膜瘤、松果体瘤、成血细胞瘤、声带神经瘤、脑膜瘤、成神经细胞瘤、成视神经细胞瘤、成视网膜细胞瘤、神经纤维瘤、纤维肉瘤、成纤维细胞瘤、纤维瘤、纤维腺瘤、纤维软骨瘤、纤维囊瘤、纤维粘液瘤、纤维骨瘤、纤维粘液肉瘤、纤维乳头状瘤、粘液肉瘤、粘液囊瘤、粘液软骨瘤、粘液软骨肉瘤、粘液软骨纤维肉瘤、粘液腺瘤、成粘液细胞瘤、脂肉瘤、脂肪瘤、脂肪腺瘤、成脂细胞瘤、脂肪软骨瘤、脂肪纤维瘤、脂肪血管瘤、粘液脂瘤、软骨肉瘤、软骨瘤、软骨肌瘤、脊索瘤、绒毛膜腺瘤、绒毛上皮瘤、成绒毛膜细胞瘤、骨肉瘤、成骨细胞瘤、骨软骨纤维瘤、骨软骨肉瘤、骨软骨瘤、骨囊瘤、骨牙质瘤、骨纤维瘤、骨纤维肉瘤、血管肉瘤、血管瘤、血管脂肪瘤、血管软骨瘤、成血管细胞瘤、血管角质瘤、血管神经胶质瘤、血管内皮瘤、血管纤维瘤、血管肌瘤、血管脂肪瘤、血管淋巴管瘤、血管脂肪平滑肌瘤、血管肌脂瘤、血管肌神经瘤、血管粘液瘤、血管网状内皮瘤、淋巴管肉瘤、淋巴肉芽瘤、淋巴管瘤、淋巴瘤、淋巴粘液瘤、淋巴肉瘤、淋巴管纤维瘤、淋巴细胞瘤、淋巴上皮瘤、成淋巴细胞瘤、内皮瘤、成内皮细胞瘤、滑膜瘤、滑膜肉瘤、间皮瘤、结缔组织瘤、尤因瘤、平滑肌瘤、平滑肌肉瘤、成平滑肌瘤、平滑肌纤维瘤、横纹肌瘤、横纹肌肉瘤、横纹肌粘液瘤、急性淋巴白血病、急性骨髓性白血病、慢性病细胞、红细胞增多症、淋巴瘤、子宫内膜癌、胶质瘤、结直肠癌、甲状腺癌、尿路上皮癌或多发性骨髓瘤。
显然根据以上本申请发明人的实验证实以及相关研究文献可知,关于本文所述用途,所述疼痛为炎症引起的疼痛。
关于本文所述用途,所制得的药物还可包含与所示化合物联合使用的其他化合物或药剂。其他化合物或药剂也可用于预防、治疗或改善疼痛。
关于本文所述用途,所制得的药物包含特定剂量范围的所示化合物或其盐或溶剂合物,和/或,所制得的药物为特定剂型、特定给药方式施用。
用于预防、治疗或改善疼痛的药物或该药物中包含的所示化合物或其盐或溶剂合物的剂量通常取决于施用的具体化合物、患者、具体疾病或病症及其严重程度、给药途径和频率等,并且需要由主治医师根据具体情况判定。例如,在通过口服途径施用本发明提供的化合物或药物时,其剂量可为0.1至30mg/7天,优选1至10mg/7天,进一步优选5mg/天;所述剂量可以分每7天1至2次给药,优选1次。
关于本文所述用途,所制得的药物还可包含药学上可接受的辅料或赋形剂。所述药物可以为临床施用的任何剂型,例如片剂、栓剂、分散片、肠溶片、咀嚼片、口崩片、胶囊、糖衣剂、颗粒剂、干粉剂、口服溶液剂、注射用小针、注射用冻干粉针或大输液。根据具体剂型和施用方式,所述药物中的药学上可接受的辅料或赋形剂可以包括下述的一种或多种:稀释剂、增溶剂、崩解剂、悬浮剂、润滑剂、粘合剂、填充剂、矫味剂、甜味剂、抗氧化剂、表面活性剂、防腐剂、包裹剂、和色素等。
基于本发明提供的所述用途,本发明还涉及一种疼痛的预防、治疗或改善方法,所述方法包括向有此需要的受试者施用预防、治疗或改善有效量的本发明所示化合物或者其药学上可接受的盐或溶剂合物。优选地,所述受试者是哺乳动物,更优选是人。所述疼痛为癌症引起的疼痛,癌症包括但不限于:肺癌、非小细胞肺癌、肝癌、胰腺癌、胃癌、骨癌、食道癌、乳房癌、前列腺癌、睾丸癌、结肠癌、卵巢癌、膀胧癌、子宫颈癌、黑色素瘤、鳞状细胞癌、基底细胞癌、腺癌、汗腺癌、皮脂腺癌、乳头状癌、乳头状腺癌、囊性腺癌、囊性癌、髓状癌、支气管癌、骨细胞癌、上皮癌、胆管癌、绒毛膜癌、胚癌、精原细胞癌、维尔姆斯癌、胶质细胞癌、星形细胞瘤、成神经管细胞瘤、颅咽管瘤、室管膜瘤、松果体瘤、成血细胞瘤、声带神经瘤、脑膜瘤、成神经细胞瘤、成视神经细胞瘤、成视网膜细胞瘤、神经纤维瘤、纤维肉瘤、成纤维细胞瘤、纤维瘤、纤维腺瘤、纤维软骨瘤、纤维囊瘤、纤维粘液瘤、纤维骨瘤、纤维粘液肉瘤、纤维乳头状瘤、粘液肉瘤、粘液囊瘤、粘液软骨瘤、粘液软骨肉瘤、粘液软骨纤维肉瘤、粘液腺瘤、成粘液细胞瘤、脂肉瘤、脂肪瘤、脂肪腺瘤、成脂细胞瘤、脂肪软骨瘤、脂肪纤维瘤、脂肪血管瘤、粘液脂瘤、软骨肉瘤、软骨瘤、软骨肌瘤、脊索瘤、绒毛膜腺瘤、绒毛上皮瘤、成绒毛膜细胞瘤、骨肉瘤、成骨细胞瘤、骨软骨纤维瘤、骨软骨肉瘤、骨软骨瘤、骨囊瘤、骨牙质瘤、骨纤维瘤、骨纤维肉瘤、血管肉瘤、血管瘤、血管脂肪瘤、血管软骨瘤、成血管细胞瘤、血管角质瘤、血管神经胶质瘤、血管内皮瘤、血管纤维瘤、血管肌瘤、血管脂肪瘤、血管淋巴管瘤、血管脂肪平滑肌瘤、血管肌脂瘤、血管肌神经瘤、血管粘液瘤、血管网状内皮瘤、淋巴管肉瘤、淋巴肉芽瘤、淋巴管瘤、淋巴瘤、淋巴粘液瘤、淋巴肉瘤、淋巴管纤维瘤、淋巴细胞瘤、淋巴上皮瘤、成淋巴细胞瘤、内皮瘤、成内皮细胞瘤、滑膜瘤、滑膜肉瘤、间皮瘤、结缔组织瘤、尤因瘤、平滑肌瘤、平滑肌肉瘤、成平滑肌瘤、平滑肌纤维瘤、横纹肌瘤、横纹肌肉瘤、横纹肌粘液瘤、急性淋巴白血病、急性骨髓性白血病、慢性病细胞、红细胞增多症、淋巴瘤、子宫内膜癌、胶质瘤、结直肠癌、甲状腺癌、尿路上皮癌或多发性骨髓瘤。
基于本发明提供的所述用途,本发明还提供一种含有上文定义的式I 或式II化合物且用于预防、治疗或改善癌症或炎症引起的疼痛的药物。
基于本发明提供的所述用途,本发明还提供一种治疗癌症或炎症引起的疼痛的方法,其包含施加上述的药物的步骤;以及使用AKR1C3 抗体测定患者的癌细胞的AKR1C3还原酶含量的步骤,若测得该 AKR1C3还原酶含量等于或大于预定值,则向该患者投与上述的药物。
附图说明
图1为AST-3424是否施加对还原黄体酮生成过程的影响实验。
图2为在无AST-3424前药的条件下,前列腺素的转化过程。
图3为在有AST-3424前药的条件下,可能的前列腺素转化过程。
具体实施方式
以下参照具体的实施例来说明本发明。本领域技术人员能够理解,这些实施例仅用于说明本发明,其不以任何方式限制本发明的范围。
下述实施例中的实验方法,如无特殊说明,均为常规方法。下述实施例中所用的药材原料、试剂材料等,如无特殊说明,均为市售购买产品。
本发明所示化合物以及合成方法见专利申请PCT/US2016/021581 (WO2016/145092)、专利申请PCT/US2016/025665(WO2016/161342) 和专利申请PCT/US2016/062114(WO2017/087428)。
提供以下定义以帮助阅读者。除非另有定义,否则本文所用的所有业内术语、符号及其他科学或医学术语或术语学均意欲具有熟习化学及医学领域的技术者通常所了解的含义。在一些情形下,为清楚和/或供及时参考,具有通常所了解含义的术语定义于本文中,且本文中此等定义的纳入不应解释为表示与如业内通常所了解的术语的定义有实质差异。
所有数值指定(例如pH、温度、时间、浓度及重量)(包括其中每一者的范围)通常可为适当以0.1、1.0或10.0的增量改变(+)或(-)的近似值。所有数值指定均可理解为前面有术语“约”。本文所述试剂为实例性的且此等的同等物可为业内所已知。
基团前的“Cx-Cy”或“Cx-y”是指存在于该基团中的碳原子数目的范围。举例而言,C1-C6烷基是指具有至少1个且最多6个碳原子的烷基。
“烷氧基”是指-O-烷基。
“胺基”是指NRpRq,其中Rp及Rq独立是氢或C1-C6烷基,或Rp及 Rq与其所键结的氮原子一起形成4-15元杂环。
“芳基”是指具有6至14个碳原子且不含环杂原子且具有单环(例如,苯基)或多个缩合(稠合)环(例如,萘基或蒽基)的芳香族基团。对于包括不具有环杂原子之具有芳香族环及非芳香族环之稠合、桥连及螺环系统之多环系统而言,当附接点位于芳香族碳原子处时,术语“芳基”或“Ar”适用(例如,5,6,7,8四氢萘-2-基是芳基,此乃因其附接点是位于芳香族苯基环的2 位处)。
根据本申请的具体实施方式,C6-C10芳基可以是苯基、萘基及各种取代的苯基或萘基。
“杂芳基”是指具有1至14个碳原子及1至6个选自由氧、氮及硫组成的群的杂原子的芳香族基团且包括单环(例如咪唑基-2-基及咪唑-5- 基)及多环系统(例如咪唑并吡啶基、苯并三唑基、苯并咪唑-2-基及苯并咪唑-6-基)。对于包括具有芳香族及非芳香族环的稠合、桥连及螺环系统的多环系统而言,若存在至少一个环杂原子且附接点是位于芳香族环的原子处,则应用术语“杂芳基”(例如1,2,3,4-四氢喹啉-6-基及5,6,7,8- 四氢喹啉-3-基)。在一些实施例中,杂芳基的氮和/或硫环原子视情况经氧化以提供N-氧化物(N→O)、亚磺酰基或磺酰基部分。术语杂芳基或 5-15元杂芳基包括(但不限于)吖啶基、吖辛因基(azocinyl)、苯并咪唑基、苯并呋喃基、苯并硫代呋喃基、苯并噻吩基(benzothiophenyl)、苯并恶唑基、苯并噻唑基、苯并三唑基、苯并四唑基、苯并异恶唑基、苯并异噻唑基、苯并噻吩基(benzothienyl)、苯并咪唑啉基、咔唑基、NH-咔唑基、咔啉基、苯并二氢吡喃基(chromanyl)、苯并吡喃基(chromenyl)、噌啉基(cinnolinyl)、二噻嗪基、呋喃基、呋呫基、咪唑啶基、咪唑啉基、咪唑并吡啶基、咪唑基、吲唑基、二氢吲哚基(indolenyl)、吲哚啉基、吲嗪基、吲哚基、异苯并呋喃基、异苯并二氢吡喃基(isochromanyl)、异吲唑基、异吲哚啉基、异吲哚基、异喹啉基(isoquinolinyl)、异喹啉基 (isoquinolyl)、异噻唑基、异恶唑基、萘啶基、八氢异喹啉基、恶二唑基、恶唑啶基、恶唑基、嘧啶基、啡啶基、啡啉基、吩嗪基、吩噻嗪基、吩恶噻基、吩恶嗪基、酞嗪基、六氢吡嗪基、蝶啶基、嘌呤基、吡喃基、吡嗪基、吡唑啶基、吡唑啉基、吡唑基、唑嗪基、吡啶并恶唑基、吡啶并咪唑基、吡啶并噻唑基、吡啶基(pyridinyl)、吡啶基(pyridyl)、嘧啶基、吡咯基、喹唑啉基、喹啉基、喹喏啉基、奎宁环基、四氢异喹啉基、四氢喹啉基、四唑基、噻二嗪基、噻二唑基、噻蒽基、噻唑基、噻吩基(thienyl)、噻吩并噻唑基、噻吩并恶唑基、噻吩并咪唑基、噻吩基 (thiophenyl)、三嗪基及呫吨基。
“烷基”是指具有1至10个碳原子且在一些实施例中具有1至6个碳原子的单价饱和脂肪族烃基。“Cx-y烷基”是指具有x至y个碳原子的烷基。此术语包括(举例而言)直链及具支链烃基,例如甲基(CH3-)、乙基 (CH3CH2-)、正丙基(CH3CH2CH2-)、异丙基((CH3)2CH-)、正丁基(CH3CH2CH2CH2-)、异丁基((CH3)2CHCH2-)、第二丁基 ((CH3)(CH3CH2)CH-)、第三丁基((CH3)3C-)、正戊基 (CH3CH2CH2CH2CH2-)及新戊基((CH3)3CCH2-)。
“环烷基”是指具有3至14碳原子且没有环杂原子且具有单环或包括稠合、桥连及螺环系统的多环的饱和或部分饱和环状基团。对于不具有环杂原子的具有芳香族及非芳香族环的多环系统而言,当附接点是位于非芳香族碳原子处时,术语“环烷基”适用(例如5,6,7,8-四氢萘-5-基)。术语“环烷基”或C3-C8环烷基包括环烯基。环烷基或C3-C8环烷基的实例包括(例如)金刚烷基、环丙基、环丁基、环戊基、环辛基及环己烯基。
“杂环状”或“杂环”或“杂环烷基”或“杂环基”是指具有1至14个碳原子及1至6个选自由氮、硫或氧组成的群的杂原子的饱和或部分饱和环状基团且包括单环及包括稠合、桥连及螺环系统的多环系统。对于具有芳香族及/或非芳香族环的多环系统而言,当存在至少一个环杂原子且附接点是位于非芳香族环的原子处时,术语“杂环状”、“杂环”、“杂环烷基”或“杂环基”适用(例如1,2,3,4-四氢喹啉-3-基、5,6,7,8-四氢喹啉 -6-基及十氢喹啉-6-基)。在一些实施例中,此处杂环基是3-15元、4-14 元、5-13元、7-12或5-7元杂环。在一些其他实施例中,杂环含有4个杂原子。在一些其他实施例中,杂环含有3个杂原子。在另一实施例中,杂环含有最多2个杂原子。在一些实施例中,杂环基的氮及/或硫原子视情况经氧化以提供N-氧化物、亚磺酰基、磺酰基部分。杂环基包括(但不限于)四氢吡喃基、六氢吡啶基、N-甲基六氢吡啶-3-基、六氢吡嗪基、 N-甲基吡咯啶-3-基、3-吡咯啶基、2-吡咯啶酮-l-基、吗啉基及吡咯啶基。指示碳原子数的前缀(例如,C3-10)是指杂环基部分中除杂原子数之外的总碳原子数。二价杂环基将具有适当调整的氢含量。
“醚”是指经1-3个C1-C6烷氧基取代的C1-C6烷基。烷氧基是指-O- 烷基。
“卤基”是指氟、氯、溴及碘中的一或多者。
“烯基”是指具有2至10个碳原子且在一些实施例中2至6个碳原子或2至4个碳原子且具有至少1个乙烯基不饱和位点(>C=<)的直链或具支链烃基。举例而言,Cx-y烯基是指具有x至y个碳原子的烯基且意欲包括(例如)乙烯基、丙烯基、1,3-丁二烯基及诸如此类。
“炔基”是指2至10个碳原子且在一些实施例中2至6个碳原子或2 至4个碳原子且含有至少一个三键的直链单价烃基或具支链单价烃基。术语“炔基”亦意欲包括具有一个三键及一个双键的这些烃基。举例而言, C2-6炔基包括乙炔基、丙炔基及诸如此类。
“胺基磷酸酯烷化剂”是指包含一或多个键结至-O-P(Z1)部分的 Z5-X5-Y5部分的烷化剂,其中Z5是诸如氮、硫或氧等杂原子,X5是视情况经取代的伸乙基,Y5是卤基或另一离去基,或Z5-X5-Y5一起形成氮丙啶基(NCH2CH2)部分且Z1如上文所定义。此一烷化剂可与DNA或另一核酸或蛋白质反应。在一些情形下,烷化剂可交联DNA。
术语“视情况经取代”是指经取代或未经取代的基团。基团可经一或多个取代基(例如1、2、3、4或5个取代基)取代。较佳地,取代基选自由以下组成的群:侧氧基、卤基、-CN、NO2、-N2+、-CO2R100、-OR100、-SR100、 -SOR100、-SO2R100、-NR100SO2R100、-NR101R102、-CONR101R102、 -SO2NR101R102、C1-C6烷基、C1-C6烷氧基、-CR100=C(R100)2、-CCR100、 C3-C10环烷基、C3-C10杂环基、C6-C12芳基及C2-C12杂芳基或诸如 -O-(CH2)-O-、-O-(CH2)2-O-及其1-4个甲基经取代的形式等二价取代基,其中R100、R101及R102各自独立是氢或C1-C8烷基;C3-C12环烷基;C3-C10杂环基;C6-C12芳基;或C2-C12杂芳基;或R100及R102与其附接至的氮原子一起形成5-7元杂环;其中烷基、环烷基、杂环基、芳基或杂芳基各自视情况经1-3个卤基、1-3个C1-C6烷基、1-3个C1-C6卤烷基或1-3个 C1-C6烷氧基取代。较佳地,取代基选自由以下组成的群:氯、氟、-OCH3、甲基、乙基、异丙基、环丙基、-CO2H及其盐及C1-C6烷基酯、CONMe2、 CONHMe、CONH2、-SO2Me、-SO2NH2、-SO2NMe2、-SO2NHMe、 -NHSO2Me、-NHSO2CF3、-NHSO2CH2Cl、-NH2、-OCF3、-CF3及-OCHF2。
“伸烷基”(Alkylene)是指具有1至10个碳原子且在一些实施例中具有1至6个碳原子的二价饱和脂肪族烃基。“Cu-v伸烷基”是指具有u至v 个碳原子的伸烷基。亚烷基(Alkylidene)及伸烷基包括具支链及直链烃基。举例而言,“C1-C6伸烷基”包括亚甲基、伸乙基、伸丙基、2-甲基伸丙基、伸戊基及诸如此类。
“伸杂烷基”是指其中链碳原子经诸如O、S、N或P等杂原子或含有杂原子的取代基替代的伸烷基。
在本文中关于D所述的“药物”包括(但不限于)吉西他滨 (gemcitabine)、埃罗替尼(erlotinib)、美妥替哌(meturedepa)、乌瑞替派(uredepa)、六甲蜜胺(altretamine)、伊马替尼(imatinib)、曲他胺 (triethylenemelamine)、三甲密胺、苯丁酸氮芥(chlorambucil)、萘氮芥(chlornaphazine)、雌氮芥(estramustine)、吉非替尼(gefitinib)、氮芥(mechlorethamine)、氮芥氧化物盐酸盐、美法仑(melphalan)、新氮芥(novembichin)、芬司特瑞(phenesterine)、泼尼氮芥 (prednimustine)、曲磷胺(trofosfamide)、尿嘧啶氮芥(uracil mustard)、卡莫司汀(carmustine)、氯脲菌素(chlorozotocin)、福莫司汀(fotemustine)、尼莫司汀(nimustine)、雷莫司汀(ranimustine)、达喀尔巴嗪(dacarbazine)、甘露氮芥(mannomustine)、二溴甘露醇(mitobronitol)、二溴卫矛醇(mitolactol)、哌泊溴烷(pipobroman)、阿克拉霉素(aclacinomycins)、放射菌素(actinomycin)、安曲霉素 (anthramycin)、偶氮丝胺酸(azaserine)、博莱霉素(bleomycin)、放线菌素C(cactinomycin)、卡柔比星(carubicin)、嗜癌菌素 (carzinophilin)、色霉素(chromomycin)、放线菌素d(dactinomycin)、道诺霉素(daunorubicin)、柔红霉素(daunomycin)、6-重氮-5-侧氧基 -1-正白胺酸、霉酚酸(mycophenolic acid)、诺加霉素(nogalamycin)、橄榄霉素(olivomycin)、培洛霉素(peplomycin)、普卡霉素 (plicamycin)、泊非罗霉素(porfiromycin)、嘌呤霉素(puromycin)、链黑霉素(streptonigrin)、链脲菌素(streptozocin)、杀结核菌素(tubercidin)、乌苯美司(ubenimex)、净司他丁(zinostatin)、左柔比星 (zorubicin)、迪诺特宁(denopterin)、蝶罗呤(pteropterin)、曲美沙特 (trimetrexate)、氟达拉宾(fludarabine)、6-巯基嘌呤、硫米嘌呤 (thiamiprine)、硫鸟嘌呤、安西他滨(ancitabine)、阿扎胞苷 (azacitidine)、6-氮杂尿苷、卡莫氟(carmofur)、阿糖胞苷(cytarabine)、双脱氧尿苷(dideoxyuridine)、脱氧氟尿苷(doxifluridine)、依诺他滨(enocitabine)、氟尿苷(floxuridine)、5-氟尿嘧啶、替加氟(tegafur)、L-天冬酰胺酶、百慕时(pulmozyme)、醋葡醛内酯、醛磷酰胺糖苷、胺基乙酰丙酸、安吖啶(amsacrine)、贝斯布西(bestrabucil)、比生群 (bisantrene)、得佛酰胺(defofamide)、地美可辛(demecolcine)、地吖醌(diaziquone)、艾弗鸟胺酸(elfornithine)、依利醋铵(elliptinium acetate)、依托格鲁(etoglucid)、氟他胺(flutamide)、羟基尿素(hydroxyurea)、干扰素-α、干扰素-β、干扰素-γ、介白素-2、蘑菇多醣(lentinan)、丙脒腙(mitoguazone)、米托蒽醌(mitoxantrone)、莫哌达醇(mopidamol)、二胺硝吖啶(nitracrine)、喷司他丁(pentostatin)、蛋胺氮芥(phenamet)、吡柔比星(pirarubicin)、鬼臼酸(podophyllinic acid)、2-乙基酰肼、丙卡巴肼(procarbazine)、雷佐生(razoxane)、西索菲兰(sizofiran)、锗螺胺(spirogermanium)、太平洋紫杉醇(paclitaxel)、他莫昔芬(tamoxifen)、埃罗替尼(erlotonib)、替尼泊苷(teniposide)、细交链孢菌酮酸(tenuazonic acid)、三亚胺醌、2,2',2"- 三氯三乙胺、尿烷、长春碱(vinblastine)及长春新碱(vincristine)。
向患者“投与”或“施用”药物是指直接投与或施用(其可由医学专业人士向患者投与或施用或者可自投与或施用)及/或间接投与或施用,其可是开处药物的行为。举例而言,指示患者自投与或施用药物及/或将药物的处方提供给患者的医师是向患者投与或施用药物。
“癌症”是指可通过侵袭而局部扩展且通过转移而全身扩展的潜在无限制生长的白血病、淋巴瘤、癌及其他恶性肿瘤(包括实体肿瘤)。癌症的实例包括(但不限于)肾上腺、骨、脑、乳房、支气管、结肠及/或直肠、胆囊、头及颈、肾、喉、肝、肺、神经组织、胰脏、前列腺、副甲状腺、皮肤、胃及甲状腺的癌症。癌症的某些其他实例包括急性及慢性淋巴细胞及粒细胞肿瘤、腺癌、腺瘤、基底细胞癌、子宫颈上皮分化不良及原位癌、尤文氏肉瘤、表皮样癌、巨细胞瘤、多型性神经胶母细胞瘤、毛细胞肿瘤、肠神经节细胞瘤、增生性角膜神经肿瘤、胰岛细胞癌、卡波西肉瘤、平滑肌瘤、白血病、淋巴瘤、恶性类癌瘤、恶性黑色素瘤、恶性高钙血症、马方样体型肿瘤、髓样上皮癌、转移性皮肤癌、黏膜神经瘤、骨髓瘤、蕈状肉芽肿、神经胚细胞瘤、骨肉瘤、骨原性及其他肉瘤、卵巢瘤、嗜铬细胞瘤、真性红血球增多症、原发性脑瘤、小细胞肺癌、溃疡型及乳头型二者的鳞状细胞癌、增生、精原细胞瘤、软组织肉瘤、视网膜母细胞瘤、横纹肌肉瘤、肾细胞肿瘤、局部皮肤病灶、网状细胞肉瘤及威尔姆氏肿瘤。
“炎症”优选由于上述花生四烯酸-环氧合酶-前列腺素途径的,由前列腺素E2/F2引发疼痛的炎症。
“患者”及“个体”可互换使用,是指需要癌症治疗的哺乳动物。通常,患者是人类。通常,患者是诊断患有癌症的人类。在某些实施例中,“患者”或“个体”可指用于筛选、表征及评估药物及疗法的非人类哺乳动物,例如非人类灵长类动物、狗、猫、兔、猪、小鼠或大鼠。
“前药”是指投与或施用之后经新陈代谢或以其他方式转化为关于至少一种性质的生物学活性或活性更高的化合物(或药物)的化合物。相对于药物,前药以使其相对于药物活性较低或无活性的方式化学修饰,但化学修饰使得在前药投与之后通过代谢或其他生物过程产生相应药物。前药可相对于活性药物具有改变的代谢稳定性或输送特征、较少副作用或较低毒性或经改良的风味(参见(例如)参考文献Nogrady,1985,MedicinalChemistry A Biochemical Approach,0xford University Press,New York,第388页至392页,其以引用式并入本文中)。前药可使用除相应药物以外的反应物来合成。
“实体肿瘤”是指包括(但不限于)骨、脑、肝、肺、淋巴结、胰脏、前列腺、皮肤及软组织(肉瘤)中的转移肿瘤的实体肿瘤。
药物的“治疗有效量”是指当向患有癌症的患者投与或施用时,将具有预期的治疗效应(例如患者中一或多种癌症的临床表现的缓和、改善、缓解或消除)的药物的量。治疗效应不必通过投与或施用一个剂量而出现,且可仅在投与或施用一系列剂量后出现。因此,治疗有效量可以一或多次来投与或施用。
病况或患者的“治疗”是指采取步骤以获得有益或期望结果(包括临床结果)。出于本发明的目的,有益或期望临床结果包括(但不限于)一或多种癌症症状的缓和或改善;疾病程度的减弱;疾病进展的延迟或减缓;疾病状态的改善、缓解或稳定;或其他有益结果。在一些情形下,癌症的治疗可使得部分反应或稳定疾病。
“肿瘤细胞”是指任何适当物种(例如,哺乳动物,例如鼠类、犬、猫、马或人类)的肿瘤细胞。
以上对本发明具体实施方式的描述并不限制本发明,本领域技术人员可以根据本发明作出各种改变或变形,只要不脱离本发明的精神,均应属于本发明所附权利要求的范围。
以下提供体外实验和食蟹猴体内实验来验证化合物的止痛作用。
一、体外实验
实验仪器:
Waters Acquity I Class UPLC超高效液相色谱仪配有Xevo G2-XS Q Tof HRMS四极杆飞行时间高分辨率质谱仪。
缓冲液和物料:
1.PBS磷酸缓冲盐溶液,
2. 20mM NADPH的PBS磷酸缓冲盐溶液
3. 250μg/mL AKR1C3的PBS磷酸缓冲盐溶液
4. 250μM AST-3424的50%MeOH/H2O溶液
5. 250μM黄体酮(progesterone)的50%MeOH/H2O溶液
6. 1μg/mL普萘洛尔(propranolol)的100%乙腈溶液
实验操作流程
步骤1,将反应混合物按照下表一式四份(n=4)制成Eppendorf 管,轻轻混合。
物料 | 阴性对照(μL) | 样本(μL) |
PBS | 68 | 58 |
NADPH(20mM) | 10 | 10 |
AKR1C3(250μg/mL) | 10 | 10 |
AST-3424(250μM) | 0 | 10 |
步骤2,将以上一式两份混合物在37℃下预孵育30分钟,60分钟。
步骤3,在每个Eppendorf管中加入另外10μL的20mM NADPH的 PBS磷酸缓冲盐溶液和2μL的250μM黄体酮的50%MeOH/H2O溶液并轻轻混合。
步骤4,立即将以上步骤中的50μL混合物转移到100μL的1μg/mL 普萘洛尔(内标IS)的100%乙腈溶液中。
步骤5,将剩余样品在37℃下孵育30分钟,并加入100μL 1μg/mL普萘洛尔(内标IS)的100%乙腈溶液。
步骤6,对于所有样品,加入100μL试剂水,以1100rpm涡旋混合5 分钟,并在室温下以15000rpm离心10分钟。
步骤7,将所有样品加载到LC/MS上以测定还原的黄体酮即20α- 二氢孕酮的含量。
LC-MS仪器的测试条件为
液相洗脱梯度
Time(min) | A(%) | B(%) |
0.00 | 90.0 | 0.0 |
1.5 | 5.0 | 95.0 |
2.00 | 5.0 | 95.0 |
2.30 | 90.0 | 10.0 |
3.00 | 90.0 | 10.0 |
四极杆飞行时间质谱参数
步骤9,还原黄体酮(20α-二氢孕酮)的计算:通过LC/MS测定每种样品中还原黄体酮即20α-二氢孕酮和普萘洛尔峰面积。计算还原黄体酮与普萘洛尔的峰面积比(即上表中的比率),并将时间为0时的比率设定为0%。
AKR1C3活性(%)=[(样品标准化后的还原黄体酮量)30min-(样品标准化后的还原黄体酮量)0min]/[(阴性对照组标准化后的还原黄体酮量)30min-(阴性对照组标准化后还原黄体酮量)0min]*100。
根据以上计算得到上表的AKR1C3活性结果。
实验结果
实验结果分析与总结
AST-3424对AKR1C3活性的影响结果表
AST-3424对还原黄体酮生产过程的影响,如图1所示。
经过以上的体外实验证实,预孵育30分钟和60分钟后,5μM浓度的AST-3424基本上抑制了AKR1C3活性:与阴性对照相比,还原黄体酮即20α-二氢孕酮的产生分别降低至3.9%和9.2%,证明了AST-3424化合物及其类似的利申请PCT/US2016/021581、PCT/US2016/025665和 PCT/US2016/062114中公开的化合物是AKR1C3酶的抑制剂。
二、体内实验
3只食蟹猴,按下表进行实验。
从广西雄森灵长类开发实验有限公司购入4只雄性食蟹猴,所有动物均为体检合格、无异常的健康食蟹猴。其中3只用于给药实验,其余的动物用于制备空白血浆。
给药前、给药开始后6、24、48和72小时。经股静脉或其他合适的静脉采血1mL,置于无抗凝剂采血管中,血液样本采集后置于冰上,静置30-60分钟离心分离血清(离心条件:3500转/分钟,10分钟,2-8℃)。收集的血清分析前存放于–80℃。
血清样本中前列腺素E2和F2由常规的ELISA方法进分析。测定结果如下表。
食蟹猴单次静脉滴注给药后的血清中前列腺素E2和F2的浓度结果
食蟹猴给予0.58mg/kg的AST3424后,前列腺素E2和F2均降低,在24 小时时出现波动性的增高,推测与动物本身分泌前列腺素E2和F2的时间特点有关,表明给予AST3424后能抑制食蟹猴分泌前列腺素E2和F2。
肿瘤直接引起的疼痛和骨骼的浸润和转移产生疼痛的原因包括:骨骼直接受累和局部伤害感受器的直接激活;肿瘤压迫邻近的神经、血管和软组织;肿瘤骨浸润时释放PGE1、PGF2,而PGF2是强烈的致痛因子,以上的动物体内实验表明AST-3424化合物可以大幅降低PGF2的含量,从而达到治疗/改善癌症或肿瘤引起的疼痛的效果。
三、实验结论
以上的体外和体内实验证实上述的特异性底物即以过表达醛酮还原酶AKR1C3为标靶的DNA烷化剂能抑制醛酮还原酶AKR1C3的活性,而且动物实验证实,其能降低血液中的前列腺素E2/F2的含量,据此,可以证明上述的AST-3424化合物及其类似的利申请PCT/US2016/021581、PCT/US2016/025665和PCT/US2016/062114中公开的化合物是AKR1C3酶的抑制剂,其能阻断前列腺素E2/F2的生成,降低其含量,具有止疼作用。
Claims (12)
1.式I化合物或者其药学上可接受的盐或溶剂合物在制备用于预防、治疗或改善疼痛的药物中的用途,
其中,
X10是O、S、SO或SO2;
A是C6-C10芳基或取代芳基、5-15元杂芳基或取代杂芳基或-N=CR1R2;其中,R1和R2各自独立地是氢、C1-C6烷基、C3-C8环烷基、C6-C10芳基、4-15元杂环、5-15元杂芳基、醚、-CONR13R14或-NR13COR14;
X、Y和Z各自独立地是氢、CN、卤基、C1-C6烷基、C2-C6烯基、C2-C6炔基、C3-C8环烷基、C6-C10芳基、4-15元杂环、5-15元杂芳基、醚、-CONR13R14或-NR13COR14;
R是氢、C1-C6烷基、C2-C6烯基、C2-C6炔基、C3-C8环烷基、C6-C10芳基、4-15元杂环、5-15元杂芳基、醚、-CONR13R14或-NR13COR14;
R13和R14各自独立地是氢、C1-C6烷基、C3-C8环烷基、C6-C10芳基、4-15元杂环、5-15元杂芳基或醚,或者R13和R14基团与其所键结的氮原子一起形成5-7元杂环基;
T包含胺基磷酸酯烷化剂;且
其中所述烷基、烯基、炔基、环烷基、芳基、杂环、杂芳基、醚基视情况经取代;
2.根据权利要求1所述的用途,其中,在所述式I化合物中,T是OP(Z1)(NR30CH2CH2X1)2、OP(Z1)(NR30 2)(N(CH2CH2X1)2)、OP(Z1)(N(CH2)2)2或OP(Z1)(N(CH2CH2X1)2)2,其中R30各自独立地是氢或C1-C6烷基,或2个R30基团与其所键结的氮原子一起形成5-7元杂环基,Z1是O或S,且X1是Cl、Br或OMs或其他离去基团。
3.根据权利要求1所述的用途,其中,在所述式I化合物中,T是OP(Z1)(NHCH2CH2Cl)2、OP(Z1)(NHCH2CH2Br)2、OP(Z1)(NH2)(N(CH2CH2X1)2)、OP(Z1)(N(CH2)2)2或OP(Z1)(N(CH2CH2Cl)2)2,其中Z1是O或S,且X1是Cl、Br或OMs。
4.根据权利要求1所述的用途,其中,在所述式I化合物中,T是OP(O)(N(CH2CH2))2、OP(O)(NHCH2CH2Cl)2、OP(O)(NHCH2CH2Br)2或OP(O)(NH2)(N(CH2CH2Cl)2)。
5.式II化合物或者其药学上可接受的盐或溶剂合物在制备用于预防、治疗或改善疼痛的药物中的用途,
其中
X10是O、S、SO或SO2;
A是C6-C10芳基或取代芳基、5-15元杂芳基或取代杂芳基或-N=CR1R2;其中,R1和R2各自独立地是氢、C1-C6烷基、C3-C8环烷基、C6-C10芳基、4-15元杂环、5-15元杂芳基、醚、-CONR13R14或-NR13COR14;
X、Y和Z各自独立地是氢、CN、卤基、C1-C6烷基、C2-C6烯基、C2-C6炔基、C3-C8环烷基、C6-C10芳基、4-15元杂环、5-15元杂芳基、醚、-CONR13R14或-NR13COR14;
每个R独立地是氢、C1-C6烷基、C2-C6烯基、C2-C6炔基、C3-C8环烷基、C6-C10芳基、4-15元杂环、5-15元杂芳基、醚、-CONR13R14或-NR13COR14;
R13和R14各自独立地是氢、C1-C6烷基、C3-C8环烷基、C6-C10芳基、4-15元杂环、5-15元杂芳基或醚,或者R13和R14与其所键结的氮原子一起形成5-7元杂环基;
L1和D如说明书中定义,具体定义如下
L1选自:
其中,R40和R41独立地是氢、C1-C6烷基、C2-C6烯基、C2-C6炔基、C3-C8环烷基、C6-C10芳基、4-15元杂环或5-15元杂芳基;
R42是视情况经1-3个C1-C6烷基取代的C2-C3伸烷基或伸杂烷基;V(-)为任何阴离子,较佳为医药学上可接受的阴离子;和
D是使得D-OH为抗癌药物的部分,其中OH为脂族羟基或酚羟基,或为如本文提供的附接至磷原子的OH部分;换言之,D是抗癌药物D-OH脱去羟基后剩余的基团;
或者
L1为:
其中R40如上文所定义,R43为氢或与D一起形成杂环,且苯基部分视情况经取代;和
D是使得D-NR43H为抗癌药物的部分;换言之,D是抗癌药物D-NR43H脱去氨基或胺后剩余的基团;
或者
其中R40、R41和V如上文所定义;和
D是含有伯胺或仲胺的抗癌药物,其中该伯胺或该仲胺键接至L1;且
其中所述烷基、烯基、炔基、环烷基、芳基、杂环、杂芳基、醚基视情况经取代。
7.根据权利要求5所述的用途,其中,所述式II化合物
为式IIA-1:
其余变量如权利要求5所定义,且D是含有一级胺基或二级胺基的细胞毒性剂HNR43-D的一部分;换言之,D是细胞毒性剂HNR43-D脱去一级胺基或二级胺基后剩余的基团;
或
为式IIA-2或IIA-3:
其余变量如权利要求5所定义,且D是含有至少一个羟基的细胞毒性剂HO-D的一部分;换言之,D是细胞毒性剂HO-D脱去羟基后剩余的基团;
或
为式IIA-4、IIA-6或IIA-6-i:
其中变量如权利要求5所定义;其中,在IIA-4中,HO-D为含有至少一个羟基的细胞毒性剂;换言之,D是含有至少一个羟基的细胞毒性剂HO-D的一部分,或者说D是细胞毒性剂HO-D脱去羟基后剩余的基团;在IIA-6-i中,DNR40R41是药物;换言之,D是使得DNR40R41为抗癌药物的部分,或者D是抗癌药物DNR40R41脱离NR40R41的部分;且在IIA-6中,D是含有仲胺的药物,其中该仲胺键接至亚甲基,换言之,D是含有仲胺的药物,且通过其含有的仲胺键接至亚甲基、进而与-NR40R41相连,如以上式IIA-4、IIA-6或IIA-6-i所示;
或
为式IIA-5或IIA-7:
其中变量如权利要求5所定义;其中,在IIA-5中,DNR40R41是药物;换言之,D是使得DNR40R41为抗癌药物的部分,或者D是抗癌药物DNR40R41脱离NR40R41的部分;在IIA-7中,D是含有仲胺的药物,其中该仲胺键接至亚甲基,如以上式IIA-5或IIA-7所示。
8.根据权利要求5所述的用途,其中,
式II化合物中Z是氢或X是氢或Y是氢/卤基;
式II化合物中A是取代/未取代的C6-C10芳基或苯基或5-15元杂芳基或吡啶基或-N=CR1R2,R1和R2如权利要求5所定义;
式II化合物中,每个R是氢或R基团中的一个是氢且另一个是C1-C6烷基,或其中R基团均是如权利要求5所定义的非氢取代基或R是甲基;
式II化合物中R40、R41和R43各自独立地是氢或甲基,且R42是-CH2-CH2-或CH2-C(Me)2-;
式II化合物中D不包括胺基磷酸酯烷基化剂,诸如-P(Z1)(NR30CH2CH2X1)2、-P(Z1)(NR30 2)(N(CH2CH2X1)2)、-P(Z1)(N(CH2CH2))2或-P(Z1)(N(CH2CH2X1)2)2,其中每个R30独立地是氢或C1-C6烷基,或2个R30与其所结合的氮原子一起形成5-7元杂环基,Z1是O或S,且X1是Cl、Br或OMs,或另一离去基团。
9.根据权利要求1至8中任一项所述的用途,其中,所述盐为碱式盐或酸式盐;所述溶剂合物为水合物或醇合物。
10.根据权利要求1至8中任一项所述的用途,其中,所述疼痛为癌症或炎症引起的疼痛。
11.一种含有上述1-8中定义的式I或式II化合物且用于预防、治疗或改善癌症或炎症引起的疼痛的药物。
12.式I或式II化合物或者其药学上可接受的盐或溶剂合物在制备用于治疗癌症或炎症引起的疼痛的药物中的用途,其包含施加权利要求11所述的药物的步骤;以及使用AKR1C3抗体测定患者的癌细胞的AKR1C3还原酶含量的步骤,若测得该AKR1C3还原酶含量等于或大于预定值,则向该患者投与权利要求11所述的药物。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810745871.4A CN110693892A (zh) | 2018-07-09 | 2018-07-09 | 化合物用于制备预防、治疗或改善疼痛的药物的用途 |
CN2018107458714 | 2018-07-09 | ||
PCT/CN2019/084604 WO2020010900A1 (zh) | 2018-07-09 | 2019-04-26 | 化合物用于制备预防、治疗或改善疼痛的药物的用途 |
CN201980001988.4A CN110896605B (zh) | 2018-07-09 | 2019-04-26 | 化合物用于制备预防、治疗或改善疼痛的药物的用途 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201980001988.4A Division CN110896605B (zh) | 2018-07-09 | 2019-04-26 | 化合物用于制备预防、治疗或改善疼痛的药物的用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115317492A true CN115317492A (zh) | 2022-11-11 |
Family
ID=69143150
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810745871.4A Pending CN110693892A (zh) | 2018-07-09 | 2018-07-09 | 化合物用于制备预防、治疗或改善疼痛的药物的用途 |
CN201980001988.4A Active CN110896605B (zh) | 2018-07-09 | 2019-04-26 | 化合物用于制备预防、治疗或改善疼痛的药物的用途 |
CN202210621699.8A Pending CN115317492A (zh) | 2018-07-09 | 2019-04-26 | 化合物用于制备预防、治疗或改善疼痛的药物的用途 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810745871.4A Pending CN110693892A (zh) | 2018-07-09 | 2018-07-09 | 化合物用于制备预防、治疗或改善疼痛的药物的用途 |
CN201980001988.4A Active CN110896605B (zh) | 2018-07-09 | 2019-04-26 | 化合物用于制备预防、治疗或改善疼痛的药物的用途 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20210283151A1 (zh) |
EP (1) | EP3821884A4 (zh) |
JP (1) | JP7153972B2 (zh) |
KR (1) | KR20210029788A (zh) |
CN (3) | CN110693892A (zh) |
CA (1) | CA3105884C (zh) |
TW (1) | TWI731346B (zh) |
WO (1) | WO2020010900A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021000862A1 (zh) * | 2019-07-01 | 2021-01-07 | 深圳艾欣达伟医药科技有限公司 | Akr1c3抑制剂及医药用途 |
JP2024508678A (ja) * | 2021-02-26 | 2024-02-28 | アセンタウィッツ ファーマシューティカルズ リミテッド | Akr1c3活性化化合物の使用 |
WO2024078568A1 (zh) * | 2022-10-12 | 2024-04-18 | 深圳艾欣达伟医药科技有限公司 | Akr1c3激活抗癌前药化合物与镇痛药物联用治疗伴有疼痛的癌症患者 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103827133A (zh) * | 2011-09-29 | 2014-05-28 | 拜耳知识产权有限责任公司 | 雌甾-1,3,5(10),16-四烯-3-甲酰胺衍生物、其制备方法、包含其的药物制剂及其用于制备药物的用途 |
WO2017087428A1 (en) * | 2015-11-16 | 2017-05-26 | Threshold Pharmaceuticals, Inc. | (r)- and (s)-1-(3-(3-n,n-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-n,n'-bis (ethylene)phosphoramidate, compositions and methods for their use and preparation |
CN107530556A (zh) * | 2015-03-10 | 2018-01-02 | 深圳艾衡昊医药科技有限公司 | Dna烷化剂 |
CN108136214A (zh) * | 2015-04-02 | 2018-06-08 | 深圳艾衡昊医药科技有限公司 | 硝基苄基衍生物抗癌试剂 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5424424A (en) * | 1993-10-07 | 1995-06-13 | G. D. Searle & Co. | Tartaric acid derivatives of substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use |
CA2878485A1 (en) * | 2012-07-10 | 2014-01-16 | Bayer Pharma Aktiengesellschaft | 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments |
AP3826A (en) * | 2013-02-21 | 2016-09-30 | Bayer Pharma Aktiengellschaft | Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (akr1 c3) |
WO2015065919A1 (en) * | 2013-10-28 | 2015-05-07 | The Regents Of The University Of California | Treatment of metastatic prostate cancer |
EP3194419B1 (en) * | 2014-09-11 | 2018-09-05 | Bayer Pharma Aktiengesellschaft | 3-nitrogen or sulphur substituted oestra-1,3,5(10),16-tetraene akr1c3 inhibitors |
EP3269373A1 (en) * | 2016-07-11 | 2018-01-17 | Bayer Pharma Aktiengesellschaft | Low-dosed oral dosage form of an akr1c3 inhibitor for treatment of diseases |
TW201919644A (zh) * | 2017-09-29 | 2019-06-01 | 台灣浩鼎生技股份有限公司 | 治療血癌的方法 |
WO2020172506A1 (en) * | 2019-02-21 | 2020-08-27 | Obi Pharma Inc. | Methods of making high enantioselective secondary alcohols |
-
2018
- 2018-07-09 CN CN201810745871.4A patent/CN110693892A/zh active Pending
-
2019
- 2019-04-26 CA CA3105884A patent/CA3105884C/en active Active
- 2019-04-26 CN CN201980001988.4A patent/CN110896605B/zh active Active
- 2019-04-26 EP EP19834376.6A patent/EP3821884A4/en active Pending
- 2019-04-26 US US17/258,724 patent/US20210283151A1/en active Pending
- 2019-04-26 CN CN202210621699.8A patent/CN115317492A/zh active Pending
- 2019-04-26 JP JP2021500604A patent/JP7153972B2/ja active Active
- 2019-04-26 KR KR1020217003089A patent/KR20210029788A/ko not_active Application Discontinuation
- 2019-04-26 WO PCT/CN2019/084604 patent/WO2020010900A1/zh unknown
- 2019-06-20 TW TW108121604A patent/TWI731346B/zh active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103827133A (zh) * | 2011-09-29 | 2014-05-28 | 拜耳知识产权有限责任公司 | 雌甾-1,3,5(10),16-四烯-3-甲酰胺衍生物、其制备方法、包含其的药物制剂及其用于制备药物的用途 |
CN107530556A (zh) * | 2015-03-10 | 2018-01-02 | 深圳艾衡昊医药科技有限公司 | Dna烷化剂 |
CN108136214A (zh) * | 2015-04-02 | 2018-06-08 | 深圳艾衡昊医药科技有限公司 | 硝基苄基衍生物抗癌试剂 |
WO2017087428A1 (en) * | 2015-11-16 | 2017-05-26 | Threshold Pharmaceuticals, Inc. | (r)- and (s)-1-(3-(3-n,n-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-n,n'-bis (ethylene)phosphoramidate, compositions and methods for their use and preparation |
Also Published As
Publication number | Publication date |
---|---|
EP3821884A1 (en) | 2021-05-19 |
CN110896605B (zh) | 2022-08-30 |
KR20210029788A (ko) | 2021-03-16 |
US20210283151A1 (en) | 2021-09-16 |
CN110693892A (zh) | 2020-01-17 |
JP2021531261A (ja) | 2021-11-18 |
TW202019434A (zh) | 2020-06-01 |
JP7153972B2 (ja) | 2022-10-17 |
EP3821884A4 (en) | 2022-04-20 |
TWI731346B (zh) | 2021-06-21 |
CA3105884C (en) | 2024-01-16 |
CA3105884A1 (en) | 2020-01-16 |
WO2020010900A1 (zh) | 2020-01-16 |
CN110896605A (zh) | 2020-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11535585B2 (en) | Nitrobenzyl derivatives of anti-cancer agents | |
CN110896605B (zh) | 化合物用于制备预防、治疗或改善疼痛的药物的用途 | |
JP5204486B2 (ja) | シクロパミンアナログ及びその使用方法 | |
US8138165B2 (en) | Chromones and chromone derivatives and uses thereof | |
AU2017204436B2 (en) | Treatment of diseases involving mucin | |
CA3138197A1 (en) | Anti-cancer nuclear hormone receptor-targeting compounds | |
KR20230167053A (ko) | 암 치료를 위해 prmt5 저해제를 사용하는 병용 요법 | |
US10927070B2 (en) | Compositions and methods for treating cancer | |
JP2020531495A (ja) | 癌治療のための組成物および方法 | |
KR20050055415A (ko) | 벤즈이미다졸 유도체를 유효성분으로 함유하는 항암제 | |
JP2008514579A (ja) | 生体還元により活性化されるプロドラッグ | |
US20240124515A1 (en) | Orally active leukemia inhibitory factor (lif) antagonists for the treatment of cancer | |
WO2022236253A1 (en) | Heterocyclic compounds as kinase inhibitors | |
KR20240095421A (ko) | 암 치료를 위해 prmt5 억제제를 사용하는 병용 요법 | |
WO2024077223A1 (en) | Protein phosphatase 2a activators | |
WO2022261643A1 (en) | Treating cancers with a cyclin-dependent kinase inhibitor | |
EA045754B1 (ru) | Аналоги пентамидина и их применение | |
CN115869325A (zh) | 化合物用于制备治疗kras突变癌症患者的药物的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |